DekaBank Deutsche Girozentrale lowered its holdings in Myriad Genetics (NASDAQ:MYGN) by 14.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,151 shares of the company’s stock after selling 6,642 shares during the period. DekaBank Deutsche Girozentrale owned about 0.06% of Myriad Genetics worth $1,158,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. LS Investment Advisors LLC increased its position in shares of Myriad Genetics by 88.5% in the fourth quarter. LS Investment Advisors LLC now owns 4,791 shares of the company’s stock worth $165,000 after acquiring an additional 2,250 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of Myriad Genetics by 58.3% in the fourth quarter. Meeder Asset Management Inc. now owns 5,210 shares of the company’s stock worth $179,000 after acquiring an additional 1,918 shares in the last quarter. BB&T Securities LLC increased its position in shares of Myriad Genetics by 347.7% in the fourth quarter. BB&T Securities LLC now owns 5,990 shares of the company’s stock worth $205,000 after acquiring an additional 4,652 shares in the last quarter. LPL Financial LLC purchased a new position in shares of Myriad Genetics in the fourth quarter worth approximately $226,000. Finally, SG Americas Securities LLC increased its position in shares of Myriad Genetics by 42.2% in the fourth quarter. SG Americas Securities LLC now owns 6,673 shares of the company’s stock worth $229,000 after acquiring an additional 1,979 shares in the last quarter.
Get Myriad Genetics alerts:Several research firms have recently weighed in on MYGN. Goldman Sachs began coverage on shares of Myriad Genetics in a research report on Monday, January 29th. They issued a “sell” rating and a $32.00 target price on the stock. Barclays lifted their target price on shares of Myriad Genetics from $30.00 to $35.00 and gave the stock an “equal weight” rating in a research report on Monday, January 22nd. BidaskClub raised shares of Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. Zacks Investment Research downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, Leerink Swann lifted their target price on shares of Myriad Genetics from $33.00 to $35.00 and gave the stock a “market perform” rating in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Myriad Genetics currently has a consensus rating of “Hold” and an average target price of $31.17.
Shares of Myriad Genetics opened at $35.40 on Friday, according to Marketbeat. Myriad Genetics has a 52 week low of $19.75 and a 52 week high of $41.57. The company has a market cap of $2.44 billion, a P/E ratio of 33.71, a P/E/G ratio of 3.77 and a beta of 0.51. The company has a current ratio of 3.52, a quick ratio of 3.16 and a debt-to-equity ratio of 0.07.
Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, May 8th. The company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.04. Myriad Genetics had a net margin of 17.67% and a return on equity of 9.52%. The firm had revenue of $193.50 million for the quarter, compared to the consensus estimate of $188.22 million. During the same period in the previous year, the firm posted $0.27 earnings per share. The firm’s revenue was down 1.7% on a year-over-year basis. equities research analysts predict that Myriad Genetics will post 1.2 EPS for the current year.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics (NASDAQ:MYGN).
